Algae related regulation & legislation

Intellectual property (IP) protection is relevant to algae businesses developing novel strains, biorefinery processes, formulations and products. This chapter provides an orientation for producers who need to understand what protection is available in the EU and what obligations may arise from using algal genetic material. It is not a substitute for specialist IP legal advice.

Patents protect technical inventions — novel, inventive, and industrially applicable solutions to technical problems. In the EU, patents are obtained either through national patent offices or, for unitary protection across participating EU member states, through the European Patent Office (EPO) under the European Patent Convention (EPC) and the Unitary Patent system operational since June 2023.

Relevance to algae:

• Novel microalgae strains developed through conventional breeding or directed evolution (not genetic modification) can in principle be patented as biological materials if they are isolated, reproducible, and meet the novelty/inventive step criteria.
• Biorefinery processes — extraction methods, cultivation processes, cell disruption methods — are patentable subject matter where novel and inventive.
• Algae-derived products and compositions — purified bioactive compounds, formulated products, encapsulated ingredients — are patentable where novel.
• GMO-derived algal innovations: genetically modified microorganisms themselves, and sequences used to modify them, are potentially patentable (the EU Biotech Directive, Directive 98/44/EC, governs the patentability of biological inventions). However, essentially biological processes for the production of plants or animals (including algae where they are treated as plants) are not patentable.

The Unitary Patent (Regulation (EU) No 1257/2012) now provides a single patent right covering all participating EU member states after grant by the EPO, significantly reducing the cost of EU-wide patent protection compared to validating European patents in each member state separately.

Plant variety rights (PVR) protect new varieties of plants, conferring exclusive rights over the production and commercialisation of propagating material. In the EU, a unitary Community Plant Variety Right (CPVR) is available through the Community Plant Variety Office (CPVO) under:

Council Regulation (EC) No 2100/94 of 27 July 1994 on Community plant variety rights, OJ L 227, 1.9.1994, p. 1.

Relevance to algae: The applicability of plant variety rights to algae is uncertain and untested. The CPVR Regulation covers plant varieties defined by their phenotypic characteristics; the CPVO examinations are designed for conventional terrestrial crops. The legal classification of algae as “plants” (which they are biologically for most macro- and microalgae, though cyanobacteria are bacteria) does not automatically mean that the CPVR system is practically accessible or administratively set up for algae. No CPVR registrations for algae species are known to exist as of 2026.

For novel algae strains with distinctive, stable and uniform commercial characteristics, patent protection under the standard biotechnology invention pathway is currently more accessible than PVR protection.

Directive (EU) 2016/943 of the European Parliament and of the Council of 8 June 2016 on the protection of undisclosed know-how and business information (trade secrets), OJ L 157, 15.6.2016, p. 1.

Relevance to algae: Trade secrets are commercially valuable information kept confidential and subject to reasonable measures to maintain that confidentiality. In the algae industry, trade secrets are frequently more practically protective than patents, particularly for:

• Proprietary strain performance characteristics (yield, composition, stress tolerance).
• Cultivation media formulations optimised for specific production systems.
• Biorefinery process parameters (temperature, pressure, solvent combinations, drying parameters).
• Customer and market intelligence.

The Trade Secrets Directive requires member states to protect trade secrets against unlawful acquisition, use and disclosure. Key obligations on the trade secret holder: the information must be secret, have commercial value because of its secrecy, and be subject to reasonable steps to keep it secret (confidentiality agreements, access controls, employee training). Trade secret protection is an important complement to patent strategy for algae companies, particularly for aspects of their technology that are not patentable or where maintaining a secret is commercially preferred to disclosing an invention in a patent application.

The Nagoya Protocol on Access and Benefit-Sharing (ABS), implemented in EU law by Regulation (EU) No 511/2014, is covered in detail in Environment and Use of Non-native Species. Its relevance to IP is direct: when a novel algal strain sourced from a third country's genetic resources is developed into a commercially valuable IP asset (patented strain, proprietary culture collection), the ABS obligations on benefit-sharing with the country of origin attach to that commercial utilisation. An IP strategy for an algae business built on genetic resources from third countries must integrate ABS compliance — ABS non-compliance can result in IP rights being unenforceable or the commercial exploitation being challenged.

Some algae research platforms and publicly funded projects have adopted open-source licensing or patent pool approaches, particularly in academic and biorefinery research. While this does not directly affect a commercial producer's IP strategy, awareness of open-source strain resources (e.g. from public culture collections such as CCAP, SAG or UTEX) and the IP status of strains accessed from such collections is important before commercial exploitation. Strains from public culture collections are generally available without IP restrictions, but the donor country's ABS obligations still apply if the strain was originally collected from a territory with ABS legislation.

• Patent novel processes and compositions — extraction methods, cultivation improvements, and novel product formulations are the primary patentable assets in most algae businesses; engage a patent attorney with biotech/life sciences experience early.
• Protect strain know-how as a trade secret — proprietary strain performance and cultivation parameters are often more valuable and more effectively protected as trade secrets than through patents (which require disclosure).
• Register EU trade marks for brand names — see EU Quality Schemes and Geographical Indications.
• Implement ABS compliance from the point of accessing genetic resources from third countries, not retroactively at the point of commercialisation.
• Conduct freedom-to-operate analysis before commercial launch — the algae biotechnology patent landscape has become populated with both broad platform patents and specific process claims, and third-party patent freedom-to-operate must be verified before scaling up a new production process.

See also: GMO Regulation | Environment and Use of Non-native Species | EU Quality Schemes and Geographical Indications | Regulatory Cases and Precedents

Last reviewed: June 2026.